The malaria treatment market size has grown strongly in recent years. It will grow from $1.49 billion in 2023 to $1.57 billion in 2024 at a compound annual growth rate (CAGR) of 5.1%. The growth observed in the historic period can be attributed to several key factors. These include the discovery of effective drugs for treating malaria, concerted efforts in vector control, global health initiatives aimed at combating malaria, advancements in scientific research contributing to better understanding and treatment options, and the development of health infrastructure to support malaria prevention and treatment efforts. Collectively, these factors played a crucial role in fostering growth and progress in addressing the challenges posed by malaria during the historical period.
The malaria treatment market size is expected to see strong growth in the next few years. It will grow to $1.94 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The projected expansion during the forecast period can be ascribed to factors such as the monitoring of drug resistance, the impact of climate change, the adoption of precision medicine and genomic approaches, reforms in healthcare financing, and the integration of digital health solutions. Key trends anticipated during the forecast period encompass enhancements in epidemiological surveillance, the integration of alternative medicine, advancements in malaria vaccine development, the implementation of data-driven treatment programs, and the initiation of education and training initiatives.
The anticipated surge in the prevalence of malaria is poised to drive the expansion of the malaria treatment market in the coming years. Malaria, a potentially life-threatening mosquito-borne ailment caused by the Plasmodium parasite, manifests with recurrent fever and flu-such as symptoms. This upswing in malaria cases is attributable to factors such as poverty, limited access to healthcare services, climate change, absence of robust malaria control measures, and emerging drug resistance. Malaria treatment plays a pivotal role in effectively managing and curing infections caused by the Plasmodium parasite.
The growth of the malaria treatment market is bolstered by the escalation in healthcare spending. Healthcare spending, denoting the overall financial resources allocated to the healthcare sector within a specific region, country, or organization, is instrumental in efficiently managing and preventing the proliferation of the disease. This involves ensuring access to timely diagnosis, antimalarial medications, and preventive measures. As an illustrative example, a report from the American Medical Association in March 2023 revealed a 2.7% increase in health spending in the United States in 2021, reaching $4.3 trillion, equivalent to $12,914 per capita. Consequently, the upsurge in healthcare spending is a key driver fueling the growth of the malaria treatment market in the foreseeable future.
The malaria treatment market is witnessing a notable trend with the emergence of novel diagnostic technologies, a development gaining traction among companies in the industry. To maintain their competitive edge, companies in the malaria treatment market are increasingly embracing innovative diagnostic malaria detection technologies. An example is Sysmex America Inc., a US-based developer and manufacturer of automated diagnostic technology, which introduced the XN-30 in October 2021. This automated hematology analyzer incorporates features such as a violet laser, specialized reagents, and advanced algorithms, enabling the differentiation of malarial strains such as P. falciparum and non-falciparum species, along with understanding their life cycle staging. Such advancements in detection contribute to the effective management of malaria treatment and patient recovery.
Major players in the malaria treatment market are adopting a strategic partnership approach to expedite the elimination of relapsing P. vivax malaria. Strategic partnerships involve companies leveraging each other's strengths and resources for mutual benefits and success. An illustrative example is the collaboration between PATH, a US-based nonprofit global health organization, and Medicines for Malaria Venture (MMV), a Switzerland-based foundation specializing in antimalarial drug research and development. This partnership aims to advance the development of quality-assured, child-friendly treatments for relapse prevention, generate evidence to support malaria-endemic countries in developing and implementing new strategies for P. vivax malaria elimination, and promote the development and availability of quality-assured medicines and diagnostics for P. vivax.
In November 2022, Novartis AG, a Switzerland-based pharmaceutical and healthcare company, joined forces with Medicines for Malaria Venture to conduct phase III clinical trials for a novel ganaplacide and lumefantrine-SDF medication combination targeting malaria in both adults and children. Medicines for Malaria Venture (MMV), as a Switzerland-based non-profit organization focused on antimalarial drug research and development, underscores the collaborative efforts within the industry to advance malaria treatment solutions.
Major companies operating in the malaria treatment market report are Pfizer Inc., Merck & Co., Johnson & Johnson, Roche Holding AG, Bayer AG, Novartis AG, Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC., Takeda Pharmaceutical Company Limited, Sumitomo Chemical Co. Ltd., Viatris Inc., Mylan N.V., Sandoz International GmbH, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Serum Institute of India, Cipla Ltd., Amneal Pharmaceuticals LLC, Lupin Ltd., Zydus Lifesciences Limited, Ipca Laboratories Ltd., Chongqing Holley Pharmaceutical Co. Ltd., Zydus Lifesciences Ltd., Medicines Sans Frontières (Doctors Without Borders), Strides Pharma Science Limited, Swiss Tropical and Public Health Institute (Swiss TPH), Aprecia Pharmaceuticals LLC, AdvaCare Pharma USA LLC, Medicines for Malaria Venture (MMV), VLP Therapeutics LLC, Actiza Pharmaceutical Private Limited.
Middle East and Africa was the largest region in the malaria treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malaria treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the malaria treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary components of malaria treatment include prescription medications, vaccines, diagnostic tests, and other therapeutic approaches. Prescription medications are pharmaceuticals that require a valid prescription from a healthcare professional. In the context of malaria treatment, these drugs are essential for providing targeted and regulated therapy to combat the infection. They can be administered through oral, parenteral, and intravenous routes and are distributed through various channels such as direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. These channels serve hospitals, specialty clinics, home care settings, and other end users, ensuring a comprehensive reach for malaria treatment options.
The malaria treatment market research report is one of a series of new reports that provides malaria treatment market statistics, including malaria treatment industry global market size, regional shares, competitors with a malaria treatment market share, detailed malaria treatment market segments, market trends and opportunities, and any further data you may need to thrive in the malaria treatment industry. This malaria treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The malaria treatment market consists of sales of antimicrobial medications, antimalarial drugs, antipyretics, intravenous fluids, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The malaria treatment market size is expected to see strong growth in the next few years. It will grow to $1.94 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The projected expansion during the forecast period can be ascribed to factors such as the monitoring of drug resistance, the impact of climate change, the adoption of precision medicine and genomic approaches, reforms in healthcare financing, and the integration of digital health solutions. Key trends anticipated during the forecast period encompass enhancements in epidemiological surveillance, the integration of alternative medicine, advancements in malaria vaccine development, the implementation of data-driven treatment programs, and the initiation of education and training initiatives.
The anticipated surge in the prevalence of malaria is poised to drive the expansion of the malaria treatment market in the coming years. Malaria, a potentially life-threatening mosquito-borne ailment caused by the Plasmodium parasite, manifests with recurrent fever and flu-such as symptoms. This upswing in malaria cases is attributable to factors such as poverty, limited access to healthcare services, climate change, absence of robust malaria control measures, and emerging drug resistance. Malaria treatment plays a pivotal role in effectively managing and curing infections caused by the Plasmodium parasite.
The growth of the malaria treatment market is bolstered by the escalation in healthcare spending. Healthcare spending, denoting the overall financial resources allocated to the healthcare sector within a specific region, country, or organization, is instrumental in efficiently managing and preventing the proliferation of the disease. This involves ensuring access to timely diagnosis, antimalarial medications, and preventive measures. As an illustrative example, a report from the American Medical Association in March 2023 revealed a 2.7% increase in health spending in the United States in 2021, reaching $4.3 trillion, equivalent to $12,914 per capita. Consequently, the upsurge in healthcare spending is a key driver fueling the growth of the malaria treatment market in the foreseeable future.
The malaria treatment market is witnessing a notable trend with the emergence of novel diagnostic technologies, a development gaining traction among companies in the industry. To maintain their competitive edge, companies in the malaria treatment market are increasingly embracing innovative diagnostic malaria detection technologies. An example is Sysmex America Inc., a US-based developer and manufacturer of automated diagnostic technology, which introduced the XN-30 in October 2021. This automated hematology analyzer incorporates features such as a violet laser, specialized reagents, and advanced algorithms, enabling the differentiation of malarial strains such as P. falciparum and non-falciparum species, along with understanding their life cycle staging. Such advancements in detection contribute to the effective management of malaria treatment and patient recovery.
Major players in the malaria treatment market are adopting a strategic partnership approach to expedite the elimination of relapsing P. vivax malaria. Strategic partnerships involve companies leveraging each other's strengths and resources for mutual benefits and success. An illustrative example is the collaboration between PATH, a US-based nonprofit global health organization, and Medicines for Malaria Venture (MMV), a Switzerland-based foundation specializing in antimalarial drug research and development. This partnership aims to advance the development of quality-assured, child-friendly treatments for relapse prevention, generate evidence to support malaria-endemic countries in developing and implementing new strategies for P. vivax malaria elimination, and promote the development and availability of quality-assured medicines and diagnostics for P. vivax.
In November 2022, Novartis AG, a Switzerland-based pharmaceutical and healthcare company, joined forces with Medicines for Malaria Venture to conduct phase III clinical trials for a novel ganaplacide and lumefantrine-SDF medication combination targeting malaria in both adults and children. Medicines for Malaria Venture (MMV), as a Switzerland-based non-profit organization focused on antimalarial drug research and development, underscores the collaborative efforts within the industry to advance malaria treatment solutions.
Major companies operating in the malaria treatment market report are Pfizer Inc., Merck & Co., Johnson & Johnson, Roche Holding AG, Bayer AG, Novartis AG, Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC., Takeda Pharmaceutical Company Limited, Sumitomo Chemical Co. Ltd., Viatris Inc., Mylan N.V., Sandoz International GmbH, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Serum Institute of India, Cipla Ltd., Amneal Pharmaceuticals LLC, Lupin Ltd., Zydus Lifesciences Limited, Ipca Laboratories Ltd., Chongqing Holley Pharmaceutical Co. Ltd., Zydus Lifesciences Ltd., Medicines Sans Frontières (Doctors Without Borders), Strides Pharma Science Limited, Swiss Tropical and Public Health Institute (Swiss TPH), Aprecia Pharmaceuticals LLC, AdvaCare Pharma USA LLC, Medicines for Malaria Venture (MMV), VLP Therapeutics LLC, Actiza Pharmaceutical Private Limited.
Middle East and Africa was the largest region in the malaria treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malaria treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the malaria treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary components of malaria treatment include prescription medications, vaccines, diagnostic tests, and other therapeutic approaches. Prescription medications are pharmaceuticals that require a valid prescription from a healthcare professional. In the context of malaria treatment, these drugs are essential for providing targeted and regulated therapy to combat the infection. They can be administered through oral, parenteral, and intravenous routes and are distributed through various channels such as direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. These channels serve hospitals, specialty clinics, home care settings, and other end users, ensuring a comprehensive reach for malaria treatment options.
The malaria treatment market research report is one of a series of new reports that provides malaria treatment market statistics, including malaria treatment industry global market size, regional shares, competitors with a malaria treatment market share, detailed malaria treatment market segments, market trends and opportunities, and any further data you may need to thrive in the malaria treatment industry. This malaria treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The malaria treatment market consists of sales of antimicrobial medications, antimalarial drugs, antipyretics, intravenous fluids, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Malaria Treatment Market Characteristics3. Malaria Treatment Market Trends and Strategies32. Global Malaria Treatment Market Competitive Benchmarking33. Global Malaria Treatment Market Competitive Dashboard34. Key Mergers and Acquisitions in the Malaria Treatment Market
4. Malaria Treatment Market - Macro Economic Scenario
5. Global Malaria Treatment Market Size and Growth
6. Malaria Treatment Market Segmentation
7. Malaria Treatment Market Regional and Country Analysis
8. Asia-Pacific Malaria Treatment Market
9. China Malaria Treatment Market
10. India Malaria Treatment Market
11. Japan Malaria Treatment Market
12. Australia Malaria Treatment Market
13. Indonesia Malaria Treatment Market
14. South Korea Malaria Treatment Market
15. Western Europe Malaria Treatment Market
16. UK Malaria Treatment Market
17. Germany Malaria Treatment Market
18. France Malaria Treatment Market
19. Italy Malaria Treatment Market
20. Spain Malaria Treatment Market
21. Eastern Europe Malaria Treatment Market
22. Russia Malaria Treatment Market
23. North America Malaria Treatment Market
24. USA Malaria Treatment Market
25. Canada Malaria Treatment Market
26. South America Malaria Treatment Market
27. Brazil Malaria Treatment Market
28. Middle East Malaria Treatment Market
29. Africa Malaria Treatment Market
30. Malaria Treatment Market Competitive Landscape and Company Profiles
31. Malaria Treatment Market Other Major and Innovative Companies
35. Malaria Treatment Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Malaria Treatment Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on malaria treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for malaria treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Treatment: Prescription Medications; Vaccines; Diagnostic Tests; Other Treatments
2) By Route of Administration: Oral; Parenteral; Intravenous
3) By Distribution Channel: Direct Tender; Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
4) By End-user: Hospitals; Specialty Clinics; Homecare; Other End-users
Key Companies Mentioned: Pfizer Inc.; Merck & Co.; Johnson & Johnson; Roche Holding AG; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Pfizer Inc.
- Merck & Co.
- Johnson & Johnson
- Roche Holding AG
- Bayer AG
- Novartis AG
- Sanofi SA
- AstraZeneca Plc
- GlaxoSmithKline PLC.
- Takeda Pharmaceutical Company Limited
- Sumitomo Chemical Co. Ltd.
- Viatris Inc.
- Mylan N.V.
- Sandoz International GmbH
- Eisai Co. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Serum Institute of India
- Cipla Ltd.
- Amneal Pharmaceuticals LLC
- Lupin Ltd.
- Zydus Lifesciences Limited
- Ipca Laboratories Ltd.
- Chongqing Holley Pharmaceutical Co. Ltd.
- Zydus Lifesciences Ltd.
- Medicines Sans Frontières (Doctors Without Borders)
- Strides Pharma Science Limited
- Swiss Tropical and Public Health Institute (Swiss TPH)
- Aprecia Pharmaceuticals LLC
- AdvaCare Pharma USA LLC
- Medicines for Malaria Venture (MMV)
- VLP Therapeutics LLC
- Actiza Pharmaceutical Private Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 1.57 Billion |
| Forecasted Market Value ( USD | $ 1.94 Billion |
| Compound Annual Growth Rate | 5.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 32 |
